Advances of pathological diagnosis and molecular pathology of lung neuroendocrine neoplasms
10.3760/cma.j.cn112151-20230818-00079
- VernacularTitle:肺神经内分泌肿瘤病理诊断和分子病理进展
- Author:
Jianghua WU
1
;
Yanli ZHU
;
Haiyue WANG
;
Yanhui LIU
;
Dongmei LIN
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所病理科 恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142
- Keywords:
Lung neoplasms;
Neuroendocrine tumors;
Carcinoma, neuroendocrine;
Molecular diagnostic techniques
- From:
Chinese Journal of Pathology
2024;53(2):109-115
- CountryChina
- Language:Chinese
-
Abstract:
The pathological classification and diagnostic criteria for lung neuroendocrine neoplasms (NENs) in the 2021 World Health Organization (WHO) lung tumor classification are similar to the prior classifications. However, the advances on the molecular studies of lung NENs have shown that both small cell lung carcinoma and large cell neuroendocrine carcinoma are highly heterogeneous tumors with neuroendocrine characteristics and can be subclassified based on the features of genomics or transcriptomics, which are valuable in the diagnosis of lung NENs subtypes and patient treatment. In addition, it is necessary to interpret emerging concepts such as "lung neuroendocrine tumor G3" and "histological transformation" from pathological perspectives, as well as to know the novel neuroendocrine biomarkers such as INSM1 and POU2F3. This article summarized the diagnostic changes and the advances of molecular pathology of lung NENs based on the latest WHO classification and molecular research.
